News

Lupin bags US FDA approval for generic version of Pennsaid for arthritic knee pain

The product will be manufactured at Lupin’s facility in Pithampur

Lupin has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Diclofenac Sodium Topical Solution USP, 2 per cent w/w to market a generic equivalent of Pennsaid Topical Solution, 2 per cent w/w of Horizon Pharma Ireland DAC.

THIS CAN BE YOUR ADVERTISEMENT

According to the company’s statement, the product will be manufactured at Lupin’s facility in Pithampur. Diclofenac Sodium Topical Solution USP, 2 per cent w/w (RLD Pennsaid) had estimated annual sales of $484 million in the US.

Diclofenac topical solution (Pennsaid) is prescribed to relieve osteoarthritis pain in the knees. Diclofenac is in a class of medications called nonsteroidal anti-inflammatory drugs (NSAIDs). According to experts, it works by stopping the body’s production of a substance that causes pain.

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Back to top button
Close
Close